AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Trial: 15206667
Drug: Aripiprazole at
RxNorm normalized name: Aripiprazole
DrugBank: Aripiprazole (DB01238)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Aripiprazole at 10 mg daily
Trial: 15206667
Drug: Clozapine above
RxNorm normalized name: Clozapine
DrugBank: Clozapine (DB00363)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Clozapine above 400 mg
Trial: 15206667
Drug: Haloperidol at
RxNorm normalized name: Haloperidol
DrugBank: Haloperidol (DB00502)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Haloperidol at 3.3 to 10 mg
Trial: 15206667
Drug: High doses
RxNorm normalized name: high-density polyethylene
FDA approved: no
EMA approved: no
PMDA approved: no
Description: High doses of haloperidol
Trial: 15206667
Drug: High doses
RxNorm normalized name: high-density polyethylene
FDA approved: no
EMA approved: no
PMDA approved: no
Description: High doses of FGAs
Trial: 11388531
Drug: Epidural lidocaine
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Epidural lidocaine (15 ml; 2%) with intravenous saline placebo
Trial: 11388531
Drug: Intravenous lidocaine
RxNorm normalized name: Lidocaine
DrugBank: Lidocaine (DB00281)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Intravenous lidocaine (1 mg/kg bolus dose; 25 microg x kg(‐1) x min(‐1))
Trial: 11388531
Drug: General anesthesia
RxNorm normalized name: Ethers for general anesthesia
FDA approved: no
EMA approved: no
PMDA approved: no
Description: General anesthesia alone (intravenous saline placebo)
Trial: 9253321
Drug: Placebo (calcium
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo (calcium lactate, 500 mg/day)
Trial: 8390368
Drug: metoclopramide 20
RxNorm normalized name: metoclopramide 20 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: metoclopramide 20 mg
Trial: 8390368
Drug: saline 20
FDA approved: no
EMA approved: no
PMDA approved: no
Description: saline 20 ml
Trial: 3829698
Drug: Intravenous infusion
RxNorm normalized name: intravenous infusion pump accessory
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intravenous infusion of PTGG and steroid subconjunctival injection
Trial: 3829698
Drug: Steroid subconjunctival
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Steroid subconjunctival injection alone
Trial: 3829698
Drug: Intravenous infusion
RxNorm normalized name: intravenous infusion pump accessory
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intravenous infusion of PTGG alone
Trial: 29772657
Drug: Optimized Virgin
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Optimized Virgin Olive Oil (OVOO) (490 ppm of phenolic compounds and 86 ppm of triterpenes)
Trial: 29772657
Drug: Virgin Olive
RxNorm normalized name: Olive Oil
DrugBank: Olive oil (DB09567)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Virgin Olive Oil (VOO) (124 ppm of phenolic compounds and 86 ppm of triterpenes)
Trial: 29772657
Drug: Functional Olive
RxNorm normalized name: Olive Oil
DrugBank: Olive oil (DB09567)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Functional Olive Oil (FOO) (487 ppm of phenolic compounds and 389 ppm of triterpenes)
Trial: 29772657
Drug: Virgin Olive
RxNorm normalized name: Olive Oil
DrugBank: Olive oil (DB09567)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Virgin Olive Oil (VOO) with at least 124 ppm of phenolic compounds
Trial: 27400272
Drug: 80mg atorvastatin
RxNorm normalized name: atorvastatin 80 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 80mg atorvastatin
Trial: 19958646
Drug: Magnesium isoglycyrrhizinate
RxNorm normalized name: Magnesium
DrugBank: Magnesium (DB14513)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Magnesium isoglycyrrhizinate 100 mg once daily (group A)
Trial: 19958646
Drug: Magnesium isoglycyrrhizinate
RxNorm normalized name: Magnesium
DrugBank: Magnesium (DB14513)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Magnesium isoglycyrrhizinate 150 mg once daily (group B)
Trial: 19958646
Drug: Compound glycyrrhizin
RxNorm normalized name: glycyrrhizinate
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Compound glycyrrhizin 120 mg once daily (group C)
Trial: 15727954
Drug: Placebo and
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo and steroidogenic inhibitor
Trial: 11990404
Drug: One additional
RxNorm normalized name: Gel-One
FDA approved: no
EMA approved: no
PMDA approved: no
Description: One additional daytime 2-L exchange (intervention group)
Trial: 8134073
Drug: Metoclopramide regimen
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Metoclopramide regimen (2 mg/kg IV every 2 hours x 3)
Trial: 8134073
Drug: Ondansetron regimen
RxNorm normalized name: Ondansetron
DrugBank: Ondansetron (DB00904)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Ondansetron regimen (0.15 mg/kg IV every 4 hours x 3)
Trial: 2643902
Drug: Budesonide (400
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Budesonide (400 micrograms twice a day)
Trial: 24028597
Drug: Opalescence Boost
RxNorm normalized name: BOOST
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Opalescence Boost PF 40% gel
Trial: 21174144
Drug: H5N1 vaccine
RxNorm normalized name: Influenza H5N1 vaccine
FDA approved: no
EMA approved: no
PMDA approved: no
Description: H5N1 vaccine with AS03(A)
Trial: 21174144
Drug: H5N1 vaccine
RxNorm normalized name: Influenza H5N1 vaccine
FDA approved: no
EMA approved: no
PMDA approved: no
Description: H5N1 vaccine without AS03(A)
Trial: 19581353
Drug: Salmeterol/Fluticasone combination
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Salmeterol/Fluticasone combination (SFC) (SAL 50 microg/FP 500 microg)
Trial: 19581353
Drug: All treatments
RxNorm normalized name: All Clear
DrugBank: Ethanol (DB00898)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: All treatments (Placebo, SAL, FP, SFC)
Trial: 17356088
Drug: Herbst mandibular
RxNorm normalized name: Purslane Herb
DrugBank: Purslane (DB14327)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Herbst mandibular advancement splint (MAS) treatment for 1 year
Trial: 15094948
Drug: Nutritional supplement
RxNorm normalized name: Nutritional supplement
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Nutritional supplement with synbiotics (PS)
Trial: 15094948
Drug: Nutritional supplement
RxNorm normalized name: Nutritional supplement
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Nutritional supplement without synbiotics (P)
Trial: 9256938
Drug: Zidovudine and
RxNorm normalized name: zidovudine and lamivudine
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Zidovudine and Saquinavir (combination)
Trial: 10385495
Drug: Pravastatin 40
RxNorm normalized name: pravastatin 40 mg oral tablet
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Pravastatin 40 mg daily for 6 weeks
Trial: 8682968
Drug: 2% minoxidil
RxNorm normalized name: MINOXIDIL 2 g in 100 mL TOPICAL LIQUID [2% Minoxidil hair growth serum]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 2% minoxidil topical solution
Trial: 31307412
Drug: ML program
RxNorm normalized name: 0.4 ML Program 100 MG/ML Prefilled Syringe
FDA approved: no
EMA approved: no
PMDA approved: no
Description: ML program (10-week group sessions focusing on evidence-based parenting practices followed by the MINISTOP application for 6 months)
Trial: 23506324
Drug: Use of
RxNorm normalized name: OIL OF CAMPHOR
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Use of a vest during medication administration
Trial: 21153900
Drug: Dietary group
RxNorm normalized name: Streptococcus viridans group
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Dietary group (DG) receiving daily for 30 months, 1,200 mg of calcium and 7.5 μg of vitamin D(3) for the first 12 months, increasing to 22.5 μg for the remaining 18 months through fortified dairy products
Trial: 19618698
Drug: Dual-target condition
RxNorm normalized name: Tums Dual Action
DrugBank: Alginic acid (DB13518)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Dual-target condition (caregiver intervention + care recipient treatment)
Trial: 12153607
Drug: Ghrelin (1.0
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ghrelin (1.0 micro g/kg i.v. at 0 min)
Trial: 12153607
Drug: GHRH (1.0
FDA approved: no
EMA approved: no
PMDA approved: no
Description: GHRH (1.0 micro g/kg i.v. at 0 min)
Trial: 12153607
Drug: OGTT (100
FDA approved: no
EMA approved: no
PMDA approved: no
Description: OGTT (100 g oral glucose at -45 min)
Trial: 12153607
Drug: Li-He (Intralipid
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Li-He (Intralipid 10% 250 ml + heparin 2500 U i.v. from -30 to +120 min)
Trial: 12153607
Drug: ARG (0.5
FDA approved: no
EMA approved: no
PMDA approved: no
Description: ARG (0.5 g/kg infused from 0 to +30 min)
Trial: 7890055
Drug: Chronic low-dose
RxNorm normalized name: ethinyl estradiol
DrugBank: Ethinylestradiol (DB00977)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Chronic low-dose regimen of urinary human FSH or recombinant human FSH
Trial: 37853
Drug: Mefenorex (40
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Mefenorex (40 mg)
Trial: 37853
Drug: Fenetylline (50
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Fenetylline (50 mg)
Trial: 7082858
Drug: Corynebacterium parvum
RxNorm normalized name: Corynebacterium parvum
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Corynebacterium parvum administered intravenously on day 15 of the cytostatic cycle (group I)
Trial: 7082858
Drug: Corynebacterium parvum
RxNorm normalized name: Corynebacterium parvum
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Corynebacterium parvum administered intravenously on day 1 of the cytostatic cycle (group II)
Trial: 7082858
Drug: No administration
FDA approved: no
EMA approved: no
PMDA approved: no
Description: No administration of Corynebacterium parvum (group III)
Trial: 22713999
Drug: Acetaminophen plus
RxNorm normalized name: acetaminophen / hydrocodone Oral Capsule [Ceta Plus]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Acetaminophen plus codeine plus caffeine (T3)
Trial: 20555373
Drug: Fish-oil supplement
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Fish-oil supplement (approximately 1 g EPA and DHA)
Trial: 17907479
Drug: Ozone treatment
RxNorm normalized name: ozone
DrugBank: Ozone (DB12510)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ozone treatment and a root sealant applied to root caries lesions
Trial: 11513907
Drug: WHO short-course
FDA approved: no
EMA approved: no
PMDA approved: no
Description: WHO short-course chemotherapy
Trial: 11513907
Drug: Russian tuberculosis
RxNorm normalized name: Mycobacterium tuberculosis
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Russian tuberculosis treatment
Trial: 9051390
Drug: rhIGF‐I (80
FDA approved: no
EMA approved: no
PMDA approved: no
Description: rhIGF‐I (80 mcg/kg s.c.)
Trial: 29121961
Drug: Pain education
RxNorm normalized name: Dermoplast Pain
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Pain education program (treatment as usual)
Trial: 18979504
Drug: Beta-glucan muesli
RxNorm normalized name: Beta glucan
DrugBank: Yeast beta-D-glucan (DB19271)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Beta-glucan muesli (4.8 g oat beta-glucan)
Trial: 18979504
Drug: Combination muesli
RxNorm normalized name: combinations
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combination muesli (4.8 g oat beta-glucan plus 1.4 g stanol as PSE)
Trial: 18979504
Drug: Control muesli
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Control muesli (4.8 g control fiber)
Trial: 18979504
Drug: Beta-glucan muesli
RxNorm normalized name: Beta glucan
DrugBank: Yeast beta-D-glucan (DB19271)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Beta-glucan muesli and Combination muesli
Trial: 14738235
Drug: DNK333 (100
FDA approved: no
EMA approved: no
PMDA approved: no
Description: DNK333 (100 mg)
Trial: 9661678
Drug: Corticotropin-releasing hormone
RxNorm normalized name: corticotropin-releasing hormone
DrugBank: Corticorelin (DB05394)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Corticotropin-releasing hormone (CRH) at 2.5 micrograms/kg/hr
Trial: 9661678
Drug: Corticotropin-releasing hormone
RxNorm normalized name: corticotropin-releasing hormone
DrugBank: Corticorelin (DB05394)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Corticotropin-releasing hormone (CRH) at 4.0 micrograms/kg/hr
Trial: 7923825
Drug: 5% saline
RxNorm normalized name: Breathe Free 0.65% Saline Nasal Spray
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 5% saline infusion (0.06 ml/kg/h)
Trial: 7923825
Drug: 20% mannitol
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 20% mannitol infusion (0.07 ml/kg/h)
Trial: 2894902
Drug: Atracurium (0.4
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Atracurium (0.4 mg.kg‐1)
Trial: 2894902
Drug: d-tubocurarine (0.8
FDA approved: no
EMA approved: no
PMDA approved: no
Description: d-tubocurarine (0.8 mg.kg‐1)
Trial: 2894902
Drug: Pancuronium (0.12
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Pancuronium (0.12 mg.kg‐1)
Trial: 2894902
Drug: Vecuronium (0.07
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Vecuronium (0.07 mg.kg‐1)
Trial: 25675317
Drug: Aftercare treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Aftercare treatment (2-4 interview contacts via telephone or face-to-face within the first 3 months after discharge)
Trial: 21478141
Drug: High-voltage stimulation
FDA approved: no
EMA approved: no
PMDA approved: no
Description: High-voltage stimulation (HVS) with drug therapy
Trial: 21478141
Drug: Ultrasound with
RxNorm normalized name: Primatene with ephedrine Pill
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ultrasound with drug therapy
Trial: 21478141
Drug: Low-level laser
RxNorm normalized name: low-density polyethylene
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Low-level laser therapy (LLLT) with drug therapy
Trial: 21478141
Drug: Compression stockings
RxNorm normalized name: Truform Medical Compression Stockings
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Compression stockings with drug therapy
Trial: 21478141
Drug: Drug therapy
RxNorm normalized name: Monistat Simple Therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Drug therapy only
Trial: 21478141
Drug: Conservative HVS
RxNorm normalized name: iodine
DrugBank: Iodine (DB05382)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Conservative HVS with drug therapy
Trial: 21478141
Drug: Conservative ultrasound
RxNorm normalized name: ULTRASOUND
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Conservative ultrasound with drug therapy
Trial: 21478141
Drug: Conservative LLLT
RxNorm normalized name: Conserved dopamine neurotrophic factor
DrugBank: HER-902 (DB17948)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Conservative LLLT with drug therapy
Trial: 21478141
Drug: Conservative compression
RxNorm normalized name: oxygen
DrugBank: Oxygen (DB09140)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Conservative compression with drug therapy
Trial: 19515730
Drug: HD-FPV/RTV (1400
FDA approved: no
EMA approved: no
PMDA approved: no
Description: HD-FPV/RTV (1400 mg/100 mg twice daily)
Trial: 19515730
Drug: FPV/LPV/RTV (1400
FDA approved: no
EMA approved: no
PMDA approved: no
Description: FPV/LPV/RTV (1400 mg/533 mg/133 mg twice daily)
Trial: 19515730
Drug: STD-FPV/RTV (700
FDA approved: no
EMA approved: no
PMDA approved: no
Description: STD-FPV/RTV (700 mg/100 mg twice daily)
Trial: 17368232
Drug: Sham feedback
RxNorm normalized name: BLACK BEAN ANTI HAIR LOSS SHAM POO SET KIT
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Sham feedback therapy
Trial: 7979842
Drug: Traditional internal
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Traditional internal medicine clerkship (n=69)
Trial: 7979842
Drug: Ambulatory medicine
RxNorm normalized name: Medicaine Sting
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ambulatory medicine and ward medicine (n=38)
Trial: 7979842
Drug: Overall attitudes
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Overall attitudes towards internal medicine training
Trial: 30606271
Drug: Lurasidone (20
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Lurasidone (20 mg)
Trial: 23837278
Drug: Tramadol (50
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Tramadol (50 mg in 10 mL normal saline)
Trial: 15830221
Drug: 1.0 mg
RxNorm normalized name: HYDROCORTISONE BUTYRATE 1.0 mg in 1 g TOPICAL CREAM
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 1.0 mg alprazolam
Trial: 15830221
Drug: 2.0 mg
RxNorm normalized name: LORAZEPAM 2.0 mg in 1 mL INTRAVENOUS INJECTION
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 2.0 mg alprazolam
Trial: 15605689
Drug: Doxycin (100
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Doxycin (100 mg)
Trial: 11705752
Drug: Clonidine (up
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Clonidine (up to 0.3 mg po)
Trial: 11705752
Drug: Clonidine (0.3
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Clonidine (0.3 mg po)
Trial: 11705752
Drug: Clonidine (as
RxNorm normalized name: clonidine (as clonidine hydrochloride)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Clonidine (as low as 0.05 mg)
Trial: 9717652
Drug: Fixed combination
RxNorm normalized name: Progestogens and estrogens, fixed combinations
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Fixed combination of timolol 0.5% and latanoprost 0.001% (comb. 10)
Trial: 9717652
Drug: Fixed combination
RxNorm normalized name: Progestogens and estrogens, fixed combinations
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Fixed combination of timolol 0.5% and latanoprost 0.005% (comb. 50)
Trial: 6843197
Drug: Technicians dispensing
RxNorm normalized name: ethinyl estradiol
DrugBank: Ethinylestradiol (DB00977)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Technicians dispensing prescriptions
Trial: 6843197
Drug: Pharmacists dispensing
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Pharmacists dispensing prescriptions
Trial: 6843197
Drug: Pharmacists counseling
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Pharmacists counseling patients after technicians began dispensing prescriptions
Trial: 28375792
Drug: Idracemi, 0.3%
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Idracemi, 0.3% cortisol phosphate eye drops twice a day
Trial: 28375792
Drug: Cortivis, 0.3%
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cortivis, 0.3% cortisol phosphate in hyaluronic acid vehicle, twice a day
Trial: 21841500
Drug: Valsartan 640
RxNorm normalized name: Valsartan
DrugBank: Valsartan (DB00177)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Valsartan 640 mg/day
Trial: 11465651
Drug: Valsartan 320
RxNorm normalized name: valsartan 320 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Valsartan 320 mg/day
Trial: 21841500
Drug: Valsartan (all
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Valsartan (all doses)
Trial: 21653528
Drug: Combination antiretroviral
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combination antiretroviral therapy (ART)
Trial: 17161118
Drug: NETA/EE-24 (24-day
FDA approved: no
EMA approved: no
PMDA approved: no
Description: NETA/EE-24 (24-day regimen of norethindrone acetate 1 mg/ethinyl estradiol 20 micro g)
Trial: 17161118
Drug: NETA/EE-21 (21-day
FDA approved: no
EMA approved: no
PMDA approved: no
Description: NETA/EE-21 (21-day regimen of norethindrone acetate 1 mg/ethinyl estradiol 20 micro g)
Trial: 7972620
Drug: Beta-blocking drug
RxNorm normalized name: Beta Carotene
DrugBank: Beta carotene (DB06755)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Beta-blocking drug (Bisoprolol)
Trial: 168645
Drug: Conjugated equine
RxNorm normalized name: Conjugated equine estrogens
DrugBank: Conjugated estrogens (DB00286)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Conjugated equine oestrogen (Premarin) 1.25 mg
Trial: 168645
Drug: Conjugated equine
RxNorm normalized name: Conjugated equine estrogens
DrugBank: Conjugated estrogens (DB00286)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Conjugated equine oestrogen (Premarin) 2.5 mg
Trial: 21681533
Drug: Dexamethasone 4
RxNorm normalized name: dexamethasone 4 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Dexamethasone 4 mg (Group L)
Trial: 21681533
Drug: Dexamethasone 8
RxNorm normalized name: dexamethasone 8 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Dexamethasone 8 mg (Group H)
Trial: 16549931
Drug: IL-6 infusion
RxNorm normalized name: IL-6
DrugBank: Human interleukin-6 (DB15060)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: IL-6 infusion (n = 6)
Trial: 16549931
Drug: Saline infusion
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Saline infusion (n = 6)
Trial: 12759270
Drug: Fluticasone propionate
RxNorm normalized name: Fluticasone Propionate
DrugBank: Fluticasone propionate (DB00588)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Fluticasone propionate aqueous nasal spray (100 micro g in each nostril)
Trial: 12759270
Drug: Combination of
RxNorm normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combination of loratadine (10 mg) and montelukast sodium (10 mg) by mouth once daily
Trial: 9109607
Drug: Oral iodized
RxNorm normalized name: calcium iodized
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral iodized oil (100 mg)
Trial: 3301517
Drug: Isosorbide dinitrate
RxNorm normalized name: Isosorbide Dinitrate
DrugBank: Isosorbide dinitrate (DB00883)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Isosorbide dinitrate (both doses)
Trial: 15206484
Drug: Inositol (100
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Inositol (100 mg, twice a day)
Trial: 3912112
Drug: 2.5 mg
RxNorm normalized name: biotin 2.5 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 2.5 mg of cyclothiazide daily
Trial: 3912112
Drug: 25 mg
RxNorm normalized name: talc 25 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 25 mg of hydrochlorthiazide daily
Trial: 3912112
Drug: Increasing doses
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Increasing doses of cyclothiazide or hydrochlorthiazide
Trial: 30970404
Drug: Sublingual immunotherapy
RxNorm normalized name: Adoptive immunotherapy agent CTL019
DrugBank: Tisagenlecleucel (DB13881)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Sublingual immunotherapy (SLIT) with standardized dust mite vaccine and conventional drugs
Trial: 30970404
Drug: Placebo and
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo and conventional drugs (Control)
Trial: 30239842
Drug: Intravaginal testosterone
RxNorm normalized name: Testosterone
DrugBank: (1,2,6,7-3H)Testosterone (DB14093)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Intravaginal testosterone (IVT) cream (300 μg per dose), self-administered daily for 2 weeks and then thrice weekly for 24 weeks